REGENXBIO to Host Conference Call on November 3 to Discuss Third Quarter 2022 Financial Results, Recent Operational Highlights and Interim Data from Phase II ALTITUDE® Trial of RGX-314 for the Treatment of Diabetic Retinopathy
The Company will host a conference call on
Data Presentation Details:
Title: Suprachoroidal Delivery of RGX-314 for Diabetic Retinopathy: The Phase II ALTITUDE Study
Presenter:
Date/Time:
The presentation will be available under the Presentations & Publications page in the Media section of
Earnings Call Webcast Details:
Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.
About REGENXBIO Inc.
Contacts:
Corporate Communications
dcormack@regenxbio.com
Investors:
ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-november-3-to-discuss-third-quarter-2022-financial-results-recent-operational-highlights-and-interim-data-from-phase-ii-altitude-trial-of-rgx-314-for-the-treatment-of-diabetic-retinopathy-301660842.html
SOURCE